Pfizer is interested in acquiring Actavis in order to avoid high US taxes
Similar proposition by Pfizer was rejected for the fourth time by AstraZeneca earlier this year. Actavis has not been officially approached yet, according to Bloomberg.
Pfizer, however, is actively looking for a European company. Company registration in Europe will allow Pfizer to avoid paying a high US tax.
Source: Remedium